317 Effectiveness and safety of orodispersible Sildenafil in a new film formulation for the treatment of erectile dysfunction: comparison between Sildenafil 100 mg film-coated tablet (FCT) vs 75 mg orodispersible film (ODF)
Abstract
A new orodispersible film (ODF) formulation of Sildenafil has been developed for treatment of erectile dysfunction (ED),in order to overcome the drawbacks that some patients experience when taking the old conventional film-coated tablet (FCT).The aim is to assess the effectiveness and safety of Sildenafil ODF formulation in a group of patients with ED, who were using FCT. Between May-July 2017, 139 patients with ED were enrolled. A penile color-duplex ultrasound, medical history, hormonal evaluation and patient self-administered questionnaires were collected. All patients were administered Sildenafil 100 mg FCT for 4 weeks. Thereafter, they underwent a 2-week wash-out period and subsequently took Sildenafil 75 mg ODF for 4 weeks.IIEF-15, Hospital Anxiety and Depression Scale (HADS), Patient Global Impressions of Improvement (PGI-I) and Clinician Global Impressions of Improvement (CGI-I) questionnaires were administered. Differences of IIEF-EF, IIEF-OF, IIEF-SD and IIEF-IS mean were significantly in favor of Sildenafil 100 mg FCT, while IIEF-OS was in favor of Sildenafil 75 mg ODF. (Figure1) Significant difference in HADS changes was found in the period between wash-out to final follow-up(mean difference:-0.19;p<0.01). According to the ODF formulation, median CGI-I was 3.5(IQR:2.5-4.5)and median PGI-I was 3.0(IQR:2-0-4.0). Median action time was 20.0 minutes (IQR:15.0-30.0) and the median mouth time 60.0(IQR:30.0-120.0).Table 1:baseline characteristics
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.